BACKGROUND/OBJECTIVES: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug-drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking that would interact with hydroxychloroquine.

METHODS: We reanalyzed data from the cohort of patients 65 years and older enrolled in the MedSafer pilot study. We first identified patients taking medications with potentially harmful drug-drug interactions with hydroxychloroquine that might exclude them from participation in a typical 2019 coronavirus disease (COVID-19) therapeutic trial. Next, we identified medications that were flagged by MedSafer as potentially inappropriate and crafted guidance around medication management if contemplating the use of hydroxychloroquine.

RESULTS: The cohort contained a total of 1,001 unique patients with complete data on their home medications at admission. Of these 1,001 patients, 590 (58.9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these, 255 (43.2%) were flagged as potentially inappropriate by the MedSafer tool. Common classes of PIMs observed were antipsychotics, cardiac medications, and antidiabetic agents.

CONCLUSION: The COVID-19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID-19. J Am Geriatr Soc 68:1636-1646, 2020.

Keywords: polypharmacy; potentially inappropriate medications; hydroxychloroquine; COVID-19; deprescribing
the World Health Organization (WHO) on December 31, 2019.1,12 On March 11, 2020, the WHO declared COVID-19 a pandemic,3 and at the time of writing, greater than 4.3 million laboratory-confirmed cases have been documented globally, with more than 290,000 related deaths.4 In response, more than 600 interventional trials have been registered to investigate whether existing medications are safe and effective for the treatment of COVID-19.5

One class of medications that has demonstrated therapeutic properties in vitro are the antimalarial agents chloroquine and hydroxychloroquine.6 Following results from the early emerging literature, including several small clinical trials,7-10 an uncontrolled case series,11 and an open-label nonrandomized study from France,12 the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization for hydroxychloroquine for hospitalized patients with COVID-19 who are unable to participate in clinical trials.13-15 These studies were heavily referenced in the media despite inconclusive data, and trials for use as prophylaxis and treatment are ongoing.12,16 More recently, an observational study on hydroxychloroquine was published showing no improvement in clinical outcomes in patients hospitalized with COVID-19.17 At the present time, the FDA and the Infectious Diseases Society of America recommend against its use outside of clinical trials.18 The results of randomized controlled trials are forthcoming, and the medication may still be prescribed outside of a trial, for lack of any alternative treatment.

One population in critical need of effective treatments for COVID-19 are older adults with comorbidities such as diabetes, hypertension, and cardiac conditions. Studies suggest older adults are more susceptible to infection with COVID-19 and at a higher risk of severe complications when compared with the general population.19,20 Outbreaks in long-term care facilities resulting in death have emphasized the vulnerability of this population.21 With increasing age, higher rates of medical conditions are observed, leading to a higher prevalence of polypharmacy (taking multiple medications).22,23 As many as 56.7% of community-dwelling North Americans older than 65 years of age are taking five or more regular medications.24,25 Polypharmacy is harmful, given the association with falls, fractures, and other adverse drug events.26 However, we are now encountering another problem from taking multiple medications: a substantial risk of drug-drug interactions with potential therapies for COVID-19.27 Many of these interacting medications are potentially inappropriate medications (PIMs) that themselves carry an increased risk for adverse drug events and could be deprescribed (stopped, tapered, or switched to a safer alternative).28-31

We hypothesized that due to polypharmacy and clinically significant drug-drug interactions, many older adults with their current drug regimens will be ineligible for COVID-19 therapeutic trials and/or treatment with medications that are currently under investigation, including, but not limited to, the antimalarial hydroxychloroquine. This despite older adults being at an increased risk of complications as a result of COVID-19 and representing a population most likely to benefit from different therapeutic options. We postulated that many of these drug-drug interactions are due to PIMs that could be deprescribed proactively. In light of a recent FDA warning regarding risk of QTc prolongation, we examined hydroxychloroquine14 (as a test case) to estimate the prevalence of prescribed medications with drug-drug interactions in a cohort of hospitalized older adults with polypharmacy. We aimed to better characterize the burden of PIMs that could be deprescribed with the impetus of the COVID-19 pandemic.

METHODS

The MedSafer pilot study32 was a large controlled before and after deprescribing trial that took place between September 2016 and May 2017 on four Canadian academic internal medicine clinical teaching units. The trial was designed to assess whether a computer-assisted medication review tool augmented the deprescribing of PIMs at discharge in a population of hospitalized older adults with polypharmacy. The software’s algorithm identified PIMs and provided deprescribing recommendations for each individual patient by applying rules derived from widely available consensus documents for safer prescribing in older adults.30,31,33

Details of the trial are described elsewhere.32 Briefly, patients were identified on admission via the emergency department to one of the designated units after discussion with the treating team to see if they met the broad inclusion criteria of 65 years and older and taking five or more medications. Patient data concerning medical conditions, validated medications, and some lab results were collected and entered into the MedSafer deprescribing electronic decision support software that identified PIMs through drug-disease combinations, drug-drug interactions, or those that should be avoided or used with caution in older adults. The MedSafer system generated a report of the PIM that included a level of harm (high risk, intermediate risk, or low risk but little added value), the rationale for deprescribing, and, when appropriate, a tapering protocol.

For the present study, we reanalyzed the MedSafer data as a representative sample of vulnerable older adults with polypharmacy. We first searched the literature for medications with known drug-drug interactions with hydroxychloroquine by examining the product monograph,34 referring to drug-drug interaction websites,35,36 and reviewing the exclusion criteria for a currently enrolling FDA and Health Canada approved hydroxychloroquine trial for COVID-19 (NCT04308668).5,37,38 Medications with known interactions with hydroxychloroquine were grouped according to the American Hospital Formulary Service classification39 (Table 1) and divided into two categories: chronic medications and medications typically prescribed for a short course such as antibiotics. We analyzed all patients in the MedSafer study who consented to participate in the deprescribing trial and who had a complete medication reconciliation performed on admission.

We theoretically “exposed” this patient cohort to treatment with hydroxychloroquine (minimum 5 days at a minimum dose of 600 mg daily as in NCT04308668) and identified possible drug interactions, as well as potential harmful outcomes such as increased toxicity of hydroxychloroquine, risk of QTc prolongation or malignant cardiac arrhythmia, or risk of other adverse drug events requiring closer monitoring during therapy such as severe hypoglycemia (Table 2). From all interacting medications
### Table 1. Medications with Potential Drug-Drug Interactions with Hydroxychloroquine

| AHFS drug class | Drug name | PIM\(^3\) (Y/N) | Potential interaction with hydroxychloroquine |
|-----------------|-----------|----------------|-----------------------------------------------|
| **Chronic medications** | | | Rare but serious and potentially life-threatening side effects may occur. Can result in an increase of irregular heart rhythm, QTc prolongation, and malignant arrhythmia. Increased risk with underlying cardiac conditions or congenital/preexisting long QTc. |
| **Cardiac medications (risk of QTc prolongation)** | | | |
| 24,040,404 | Procainamide | Y | |
| 24,040,412 | Flecainide, Propafenone | | |
| 24,040,420 | Amiodarone, Ibutilide, Dofetilide | | |
| 242,400 | Sotalol | | |
| **Medications acting on the CNS (risk of QTc prolongation)** | | | |
| 28,160,416 | Venlafaxine | Y | |
| 28,160,420 | Citalopram, Escitalopram, Fluoxetine, Sertraline | | |
| 28,160,428 | Amtriptyline, Desipramine, Imipramine, Doxepin | Y | |
| 28,160,808 | Typical antipsychotics (eg, haloperidol) | Y | |
| 28,160,824 | | | |
| 28,160,804 | Atypical antipsychotics (eg, quetiapine) | Y | |
| 28,160,424 | Trazodone | Y | |
| 282,492 | Droperidol | N | |
| 2,828 | Lithium | N | |
| 404 | Promethazine | Y | |
| 404 | Hydroxyzine | Y | |
| 1,204 | Donepezil | Y | |
| 122,004 | Cyclobenzaprine | Y | |
| **Gastrointestinal/Miscellaneous (risk of QTc prolongation)** | | | |
| 563,200 | Domperidone | Y | |
| 562,220 | Ondansetron | N | |
| 861,204 | Solifenacin | Y | |
| **Other drug classes requiring increased monitoring or dose adjustment** | | | |
| 81,692 | Dapsone | N | Concomitant use of HCQ with antimalarial agents may increase the risk of hemolytic reactions. Concomitant use may increase the risk of nerve damage with longer term use (months/years). May require dose adjustment or more frequent monitoring. |
| 240,408 | Digoxin | Y | Concomitant use may result in increased serum digoxin levels. Serum digoxin levels should be closely monitored in patients receiving combined therapy. |
| 681,612 | Tamoxifen | N | Increased risk of retinal toxicity when used in combination with HCQ; greater risk with longer therapy (months/years) |
| **Medications for diabetes\(^b\)** | | | Risk of hypoglycemia |
| 682,005 | DPP-4 inhibitors | Y | |
| 682,006 | GLP-1 receptor agonist | Y | |
| 682,008 | Insulin | Y | |
| 682,016 | Meglitinides | Y | |
| 682,018 | SGLT2 inhibitors | Y | |
| 682,020 | Sulfonylureas | Y | |
| 602,028 | Thiazolidinedione | Y | |
| **Short-term use medications** | | | Rare but serious and potentially life-threatening side effects may occur. Can result in an increase of irregular heart rhythm, QTc prolongation and malignant arrhythmia. Increased risk with underlying cardiac conditions or congenital/preexisting long QTc. |
| 8,121,204 | Erythromycin | N | |
| 8,121,292 | Azithromycin (Exception: Sometimes used Chronically) | N | |
| | Clarithromycin | | |

*(Continues)*
Table 1 (Contd.)

| AHFS drug class | Drug name | PIM² (Y/N) | Potential interaction with hydroxychloroquine |
|-----------------|-----------|------------|---------------------------------------------|
| 81,218          | Levofloxacin, Ciprofloxacin, Moxifloxacin | N          |                                             |
| 81,408          | Ketoconazole, Itraconazole | N          |                                             |
| 83,092          | Chloroquine | N          | Coadministration may increase the toxic effect of antimalarials |
| 280,808         | Methadone | Y          | Coadministration of HCQ and mefloquine may increase the risk of seizure; avoid concurrent use (contraindicated) |
| 83,092          | Artemether, Lumefantrine | N          |                                             |
| 83,092          | Mefloquine | N          | Rare but serious and potentially life-threatening side effects may occur. Can result in an increase of irregular heart rhythm, QTc prolongation, and malignant arrhythmia. Increased risk with underlying cardiac conditions or congenital/ preexisting long QTc. |
| 283,228         | Sumatriptan, Zolmitriptan | N          |                                             |

Abbreviations: CNS, central nervous system; HCQ, hydroxychloroquine; N, no; PIM, potentially inappropriate medication; Y, yes.

Many of these medications are potentially inappropriate only under certain clinical circumstances (Table 2 lists potential triggering conditions).

*Metformin was not considered to be at risk of causing hypoglycemia for the purposes of this analysis.

we ran the MedSafer algorithms to determine the proportion of medications that were PIMs and that could be deprescribed. We also identified the triggering condition associated with each PIM (eg, atrial fibrillation, heart failure, dementia, delirium, or renal failure).

Finally, we developed recommendations for how to manage potential drug interaction including the option of not receiving hydroxychloroquine. Recommendations were based on the literature and expert consensus generated by the authors (experts in infectious diseases [T.C.L.,] general internal medicine [T.C.L., E.G.M., J.D., B.R., and P.E.W.], clinical pharmacy [R.W., K.B., S.P., and L.P.F.], geriatrics [A.H. and L.P.F.], and clinical pharmacology/toxicology [P.E.W.]). Ideally PIMs would be deprescribed proactively, before infection with COVID-19, but logistically this may not always be feasible, and thus we have made recommendations for these patients. Examples of recommendations included medications that can be safely and abruptly held during treatment, those that require monitoring if there is to be ongoing use, and medications that likely cannot be stopped due to risk of an adverse drug withdrawal event.

RESULTS

The MedSafer cohort contained 1,001 patients with complete data on their home medications. The median age of the cohort was 80 years; approximately 50% were women. More than one-half had hypertension, approximately 40% had diabetes, and close to 50% were moderately to severely frail as defined by the Clinical Frailty Scale. All patients were hospitalized in a tertiary care hospital and admitted to one of four general medical wards in one of three Canadian academic centers in Montreal, Ottawa, and Toronto.

We analyzed 1,001 participants and found that 590 (58.9%) were prescribed one or more usual home medications that could potentially interact with hydroxychloroquine. The most commonly prescribed drug classes with known interactions were antidiabetic medications (330/1001 [33%]), the selective serotonin/norepinephrine reuptake inhibitors (SSRIs/SNRIs) (173/1001 [17.3%]), antipsychotics (typical and atypical) (136/1001 [13.6%]), and antiarrhythmics such as digoxin and amiodarone (64/1001 [6.4%]) (Table 3). The most common classes of antidiabetics were insulin, 138 of 1,001 (13.8%), and sulfonylureas, 90 of 1,001 (9.0%) (Table 3). The most serious interaction identified was a risk of QTc prolongation, torsade de pointes, and sudden death. A common but less severe interaction was a risk of hypoglycemia requiring increased monitoring. Lowering of the seizure threshold and pharmacokinetic interactions leading to increased hydroxychloroquine levels was uncommon.

We then determined how many PIMs (as identified by the MedSafer tool) with known interactions with hydroxychloroquine presented an opportunity to be deprescribed proactively. Of the 590 of 1,001 (58.9%) of participants who were prescribed a medication that could interact with hydroxychloroquine, 255 patients had the respective medication identified as a PIM, representing 43.2% of all patients with an interacting medication. Some common deprescribing opportunities that were identified included (1) too high a dose of digoxin for a patient’s renal function, (2) antipsychotic use in patients with a known history of delirium or neurocognitive disorder (risk of stroke, falls, confusion), and (3) insulin and sulfonylureas in patients with a history of hypoglycemia and/or tight glycemic control (hemoglobin [Hb]A1c <7.5%) (Table 4).

We prepared recommendations for the management of interacting medications in patients with COVID-19 who may want to receive treatment with hydroxychloroquine if found to be effective. Examples include holding low doses of antipsychotics or antidepressants during therapy, QTc monitoring and electrolyte optimization with continued use of QTc prolonging agents, and glucose monitoring with concurrent diabetes medications. We also highlight medications such as amiodarone that cannot be stopped on short notice for inclusion in clinical trials, due to its prolonged half-life (Table 2).
Table 2 Medication Management for Potentially Inappropriate Medications with Hydroxychloroquine Interaction

| AHFS drug class | Drug name             | Triggering condition          | General rationale for deprescribing                                                                 | Suggested medication management for hydroxychloroquine interaction if unable to deprescribe in advance |
|-----------------|-----------------------|-------------------------------|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| 24,040,404      | Procainamide          | Atrial fibrillation           | Data suggest that rate control yields better balance of benefits and harms than pharmacologic rhythm control for most older adults. | If unable to deprescribe or hold during coadministration, use likely precludes HCQ given known risk of TdP for all medications listed apart from propafenone (conditional risk of TdP). Risk of sudden death. |
| 24,040,412      | Flecainide            | Atrial fibrillation           | Amiodarone is associated with multiple toxicities including thyroid disease, pulmonary disorders, and QT interval prolongation. Consider a safer alternative. | The half-life of amiodarone is 60 to 142 days for long-term oral maintenance therapy. If unable to deprescribe well in advance (weeks); likely precludes use of HCQ given known risk of TdP and risk of sudden death. |
| 24,040,420      | Dofetilide            | Atrial fibrillation           | Higher dosages of digoxin are not associated with any additional benefit and may increase risk of toxicity, especially in the presence of renal insufficiency. | If low dose (<125 μg daily) may consider holding during coadministration. Consider alternate means of rate control. If given for HF: consider holding or reducing dose during HCQ treatment. Monitor for arrhythmia, monitor electrolytes (Na, K, Mg). Monitor digoxin level if available (coadministration may increase digoxin levels). |
| 242,400         | Sotalol               |                                | Do not initiate or maintain opioids long-term for chronic pain until there has been a trial of nonpharmacologic treatment and of nonopioid medications. | Chronic methadone therapy likely precludes use of HCQ given known risk of TdP, sudden death, and risk of withdrawal syndrome from holding methadone therapy. |
| 24,040,420      | Propafenone           |                                | Keep at low dose, consider holding during therapy and monitor for early withdrawal symptoms: dizziness, GI upset, flulike symptoms, paresthesias, insomnia, and psychiatric problems. For higher doses, suggest avoiding HCQ with (es) citalopram given known risk of TdP and sudden death. Possible risk of TdP for venlafaxine and conditional risk for fluoxetine and sertraline (coadministration requires careful electrolyte and QTc monitoring). |
| 28,160,416      | Venlafaxine           |                                | Do not use trazodone for sleep disorders or as first choice for behavioral symptoms unless agitation is severe and nonpharmacologic interventions have failed. Increased risk of falls, daytime drowsiness, and impaired cognition. | If low dose, consider holding during therapy and monitor for early withdrawal symptoms. For higher doses, may consider reducing dose with careful QTc monitoring or avoiding HCQ altogether given possible risk of TdP. |
| 28,160,420      | Citalopram, Escitalopram, Fluoxetine, a Sertraline | Recurrent falls | SSRIs/SNRIs increase the risk of hyponatremia and also increase the risk of recurrent falls in older adults. | If low dose, consider holding during therapy and monitor for early withdrawal symptoms: dizziness, GI upset, flulike symptoms, paresthesias, insomnia, and psychiatric problems. For higher doses, suggest avoiding HCQ with (es) citalopram given known risk of TdP and sudden death. Possible risk of TdP for venlafaxine and conditional risk for fluoxetine and sertraline (coadministration requires careful electrolyte and QTc monitoring). |
| 28,160,424      | Trazodone             | Flagged for all older adults | Alone or in combination may precipitate or worsen delirium, urinary retention, |
| 28,160,428      | Tricyclic antidepressants, Desipramine, Imipramine, Doxepin | Dementia; urinary retention; BPH; | If low dose, consider holding during therapy and monitor for early withdrawal symptoms: |

(Continues)
| AHFS drug class | Drug name | Triggering condition | General rationale for deprescribing | Suggested medication management for hydroxychloroquine interaction // unable to deprescribe in advance |
|----------------|-----------|----------------------|------------------------------------|------------------------------------------------------------------------------------------------------------------|
|                |           | delirium; interactions with anticholinergics | constipation, glaucoma, urinary retention, and adverse CNS effects through anticholinergic effects. | dizziness, muscular pain, GI upset, headache, malaise, trouble sleeping, irritability, hyperthermia, mania. For higher doses, suggest avoiding HCQ. If used concurrently, would require QTc and electrolyte monitoring. Amitriptyline and doxepin have a conditional risk of TdP. Nortriptyline and desipramine have a possible risk of TdP. |
| 28,160,804     | Typical and atypical antipsychotics | Triggered for all patients unless history of schizophrenia or bipolar disorder | Do not use antipsychotics for sleep disorders or as first choice for behavioral symptoms unless agitation is severe and nonpharmacologic interventions have failed. Antipsychotics increase risk of stroke, falls, confusion, extrapyramidal side effects, aspiration, and death. | If low dose, consider holding during HCQ co-administration and monitoring closely for emergence of behavioral symptoms. For higher doses, may consider reducing dose with careful QTc monitoring, or alternatively, avoiding HCQ altogether (haloperidol has a known risk of TdP and sudden death). Quetiapine, risperidone, and olanzapine have a conditional risk of TdP. |
| 28,160,804     | Donepezil | Flagged in combination with beta-blockers; history of falls; orthostatic hypotension | In combination with beta-blockers can lead to bradycardia; on its own, can increase the risk of falls. | Hold medication during co-administration with HCQ but monitor for changes in behavior and development of confusion/delirium; may consider reducing dose with careful QTc monitoring, or alternatively, avoiding HCQ altogether due to known risk of TdP and sudden death. |
| 28,160,808     | Promethazine | Flagged for all older adults | Highly anticholinergic. | Hold medications during coadministration with HCQ due to possible risk of TdP. |
| 28,160,824     | Hydroxyzine | Highly anticholinergic. | Hold medication during coadministration with HCQ or monitor QTc and electrolytes due to conditional risk of QTc prolongation. |
|                | Cyclobenzaprine | Flagged for all older adults | Most muscle relaxants are poorly tolerated by older adults because of anticholinergic adverse effects, sedation, risk of fracture; effectiveness at dosages tolerated by older adults is questionable. Side effects are even more likely in patients with dementia or delirium. Taper ahead of time to avoid symptoms of withdrawal. If low dose, consider holding during HCQ coadministration and monitoring closely for behavioral symptoms. For higher doses, may consider reducing dose with careful QTc monitoring given possible QTc prolongation. |
|                | Solifenacin | Flagged for most older adults | Medications for overactive bladder symptoms may add to pill burden, contribute to adverse events from anticholinergic side effects, and the benefits rarely outweigh the harms. | Hold medication during coadministration with HCQ or monitor QTc and electrolytes due to conditional risk of QTc prolongation. |
|                | Domperidone | Parkinson’s disease | Increased risk of sudden death in Parkinson’s. | Hold medication during coadministration with hydroxychloroquine due to known risk of QTc prolongation and risk of sudden death. |

(Continues)
DISCUSSION

We reanalyzed data from the MedSafer pilot and found that one in two older adults with polypharmacy in our cohort have a chronically prescribed medication that could potentially interact with hydroxychloroquine, half of which were PIMs that could be deprescribed. The number of medical conditions and associated polypharmacy of the cohort places them at high risk of complications from COVID-19 but also potentially at risk of harm from treatments. We identified several common drug classes, many of which are also PIMs, that would preclude many older adults from enrolling in a trial. A main finding was that many older adults were taking medications that carry a known risk of Table 2 (Contd.)

| AHFS drug class | Drug name | Triggers condition | General rationale for deprescribing | Suggested medication management for hydroxychloroquine interaction if unable to deprescribe in advance |
|-----------------|-----------|--------------------|-----------------------------------|---------------------------------------------------------------------------------------------------|
| 682,005         | DPP-4 inhibitors | Diabetes; hypoglycemia; heart failure (for thiazolidinediones) | Consider decreasing if your patient had a recent hemoglobin A1c measurement <7.5%. Avoid using medications known to cause hypoglycemia. In many adults ≥65 years who are frail or with a reduced life expectancy, moderate control (HbA1c 8%-8.5%) is reasonable. Consider decreasing or stopping this medication. | Consider holding medications as per sick day protocol and monitoring glycemias closely. |
| 682,006         | GLP-1 receptor agonist | Diabetes; hypoglycemia; heart failure (for thiazolidinediones) | Consider decreasing if your patient had a recent hemoglobin A1c measurement <7.5%. Avoid using medications known to cause hypoglycemia. In many adults ≥65 years who are frail or with a reduced life expectancy, moderate control (HbA1c 8%-8.5%) is reasonable. Consider decreasing or stopping this medication. | Consider holding medications as per sick day protocol and monitoring glycemias closely. |
| 682,008         | Insulin | Diabetes; hypoglycemia; heart failure (for thiazolidinediones) | Consider decreasing if your patient had a recent hemoglobin A1c measurement <7.5%. Avoid using medications known to cause hypoglycemia. In many adults ≥65 years who are frail or with a reduced life expectancy, moderate control (HbA1c 8%-8.5%) is reasonable. Consider decreasing or stopping this medication. | Consider holding medications as per sick day protocol and monitoring glycemias closely. |
| 682,016         | Meglitinides | Diabetes; hypoglycemia; heart failure (for thiazolidinediones) | Consider decreasing if your patient had a recent hemoglobin A1c measurement <7.5%. Avoid using medications known to cause hypoglycemia. In many adults ≥65 years who are frail or with a reduced life expectancy, moderate control (HbA1c 8%-8.5%) is reasonable. Consider decreasing or stopping this medication. | Consider holding medications as per sick day protocol and monitoring glycemias closely. |
| 682,018         | SGLT2 inhibitors | Diabetes; hypoglycemia; heart failure (for thiazolidinediones) | Consider decreasing if your patient had a recent hemoglobin A1c measurement <7.5%. Avoid using medications known to cause hypoglycemia. In many adults ≥65 years who are frail or with a reduced life expectancy, moderate control (HbA1c 8%-8.5%) is reasonable. Consider decreasing or stopping this medication. | Consider holding medications as per sick day protocol and monitoring glycemias closely. |
| 862,020         | Sulfonylureas | Diabetes; hypoglycemia; heart failure (for thiazolidinediones) | Consider decreasing if your patient had a recent hemoglobin A1c measurement <7.5%. Avoid using medications known to cause hypoglycemia. In many adults ≥65 years who are frail or with a reduced life expectancy, moderate control (HbA1c 8%-8.5%) is reasonable. Consider decreasing or stopping this medication. | Consider holding medications as per sick day protocol and monitoring glycemias closely. |
| 682,028         | Thiazolidinedione | Diabetes; hypoglycemia; heart failure (for thiazolidinediones) | Consider decreasing if your patient had a recent hemoglobin A1c measurement <7.5%. Avoid using medications known to cause hypoglycemia. In many adults ≥65 years who are frail or with a reduced life expectancy, moderate control (HbA1c 8%-8.5%) is reasonable. Consider decreasing or stopping this medication. | Consider holding medications as per sick day protocol and monitoring glycemias closely. |

Table 3 Drug Interactions with Hypothetical Hydroxychloroquine on Admission

| AHFS | Generic medication name | n (%) (N = 1,001) |
|------|--------------------------|------------------|
| Cardiac medications | Digoxin | 42 (4.2) |
| | Amiodarone | 17 (1.7) |
| | Sotalol | 2 (0.2) |
| | flecainide | 2 (0.2) |
| | ibutilide | 1 (0.1) |
| | dofetilide | 0 (0) |
| | propafenone | 0 (0) |
| | procainamide | 0 (0) |
| Medications acting on the CNS | Atypical antipsychotics | 128 (12.8) |
| | Citalopram | 87 (8.7) |
| | Trazodone | 56 (5.6) |
| | Tricyclic antidepressants | 38 (3.8) |
| | Donepezil | 37 (3.7) |
| | Venlafaxine | 29 (2.9) |
| | Sertraline | 27 (2.7) |
| | Escitalopram | 24 (2.4) |
| | Hydroxyzine | 22 (2.2) |
| | Methadone | 8 (0.8) |
| | Haloperidol | 8 (0.8) |
| | Fluoxetine | 6 (0.6) |
| | Cyclobenzaprine | 3 (0.3) |
| | Lithium | 3 (0.3) |
| | Promethazine | 0 (0) |
| | Thioridazine | 0 (0) |
| | Droperidol | 0 (0) |
| Gastrointestinal/Miscellaneous medications | Domperidone | 19 (1.9) |

Table 3 (Contd.)

| AHFS | Generic medication name | n (%) (N = 1,001) |
|------|--------------------------|------------------|
| 861,204 | Solifenacin | 14 (1.4) |
| 8,121,292 | Azithromycin | 13 (1.3) |
| 562,220 | Ondansetron | 9 (0.9) |
| 81,692 | Dapsone | 3 (0.3) |
| 681,612 | Tamoxifen | 3 (0.3) |
| Medications for diabetes | Insulin | 138 (13.8) |
| | Sulfonylureas | 90 (9.0) |
| | DPP-4 inhibitors | 77 (7.7) |
| | Meglitinides | 12 (1.2) |
| | SGLT2 inhibitors | 6 (0.6) |
| | Thiazolidinedione | 4 (0.4) |
| | GLP-1 receptor agonist | 3 (0.3) |

Abbreviations: AHFS, American Hospital Formulary Service; CNS, central nervous system.

DISCUSSION

We reanalyzed data from the MedSafer pilot and found that one in two older adults with polypharmacy in our cohort have a chronically prescribed medication that could potentially interact with hydroxychloroquine, half of which were PIMs that could be deprescribed. The number of medical conditions and associated polypharmacy of the cohort places them at high risk of complications from COVID-19 but also potentially at risk of harm from treatments. We identified several common drug classes, many of which are also PIMs, that would preclude many older adults from enrolling in a trial. A main finding was that many older adults were taking medications that carry a known risk of
prolonging the QTc. This finding should caution against routine prescribing of QTc prolonging COVID-19 treatments outside of a clinical study because there is real potential for harm. Importantly, more than 50% of interacting drugs were identified as a PIM that could be proactively deprescribed, rendering the person more likely to be eligible for a trial and increasing the generalizability of study findings to this population.

In this analysis, we chose to focus on a specific drug, hydroxychloroquine. Of note, debate is ongoing regarding the safety of hydroxychloroquine for treatment of COVID-19, and studies into its efficacy are still ongoing. The risks associated with a medication such as hydroxychloroquine are likely higher for older adults with polypharmacy, especially given the common coadministration of QTc prolonging medications and the prevalence of underlying cardiac conditions.41 Many patients in our cohort were also overprescribed oral hypoglycemic agents (HbA1c<7.5% or a history of hypoglycemia) that when co-prescribed with hydroxychloroquine could increase the risk of hypoglycemia. Older adults may have decreased oral intake as a Table 4 Proportion of Potentially Inappropriate Medications That Interact with Hydroxychloroquine According to MedSafer

| Drug class or drug name | Rule (shortened): drug with triggering condition | n (%) | (total N = by class) |
|-------------------------|-------------------------------------------------|-------|---------------------|
| Agents acting on the CNS |                                                  |       |                     |
| Atypical antipsychotics (N = 128 patients) | High risk of urinary retention | 17 (13.3) |                     |
|                         | Risk of extrapyramidal symptoms in patients with parkinsonism | 9 (7.0) |                     |
|                         | Risk of stroke, falls, confusion, and extrapyramidal symptoms in patients with delirium or dementia | 40 (31.3) |                     |
| Haloperidol (N = 8 patients) | Risk of extrapyramidal symptoms in parkinsonism | 1 (12.5) |                     |
|                         | Should be avoided in patients with delirium or dementia | 4 (50.0) |                     |
| Citalopram | May contribute to additional fall risk | 6 (4.2) |                     |
| Escitalopram | Risk of exacerbating or precipitating hyponatremia | 9 (6.3) |                     |
| Fluoxetine | | | |
| Sertraline | May lead to or worsen urinary retention or delirium in patients with delirium or dementia | 5 (13.2) |                     |
| Tricyclic antidepressants (N = 38 patients) | Risk of falls and impaired cognition | 56 (100) |                     |
| Trazodone (N = 56 patients) | Risk of falls and of heart block in combination with beta-blockers | 22 (59.5) |                     |
| Donepezil (N = 37 patients) | Risk of falls and impaired cognition | 22 (100) |                     |
| Hydroxyzine (N = 22 patients) | Anticholinergic; sedating; risk of falls and fracture | 3 (37.5) |                     |
| Cyclobenzaprine (N = 3 patients) | Highly anticholinergic | 12 (85.7) |                     |
| solifenacin (N = 14 patients) | Consider risks with patient before prescribing opioid analgesics as long-term therapy to treat chronic noncancer pain | 3 (35.7) |                     |
| Methadone (N = 8 patients) | Increased risk of sudden death in Parkinson's | 1 (5.1) |                     |
| Domperidone (N = 19 patients) | | | |
| Cardiac medications | Higher dosages of digoxin may increase toxicity without additional benefit, particularly in heart failure and renal failure | 39 (92.9) |                     |
| Digoxin (N = 42 patients) | Rate control yields better balance of benefits and harms than rhythm control for most older adults | 12 (72.2) |                     |
| Amiodarone (N = 17 patients) | Associated with thyroid and pulmonary toxicity and QT prolongation | 10 (61.1) |                     |
| Class 1c antiarrhythmics (eg, flecainide, propafenone) (N = 2 patients) | Rate control yields better balance of benefits and harms than rhythm control for most older adults | 2 (100) |                     |
| Sotalol (N = 2 patients) | Rate control yields better balance of benefits and harms than rhythm control for most older adults | 1 (50.0) |                     |
| Diabetic agents | High risk of hypoglycemia (especially glyburide) | 32 (35.6) |                     |
| Sulfonylureas (N = 90 patients) | And/or | 39 (28.3) |                     |
| Insulin (N = 138 patients) | Consider decreasing or stopping in patients with HbA1c<7.5%. | 8 (10.4) |                     |
| DPP-4 inhibitors (N = 77 patients) | Moderate control (8%-8.5%) is acceptable in patients who are frail or have reduced life expectancy | 4 (33.3) |                     |
| Meglitinides (N = 12 patients) | | | |
| SGLT2 inhibitors (N = 6 patients) | | | |
| GLP-1 receptor agonist (N = 3 patients) | Potential to promote fluid retention and exacerbate heart failure | 4 (66.7) |                     |
| Thiazolidinedione (N = 4 patients) | | | |
| Thiazolidinedione (N = 4 patients) | | | |

Note: No patients were on thioridazine, procainamide, or promethazine.
No patients had venlafaxine flagged as potentially inappropriate.
Abbreviation: CNS, central nervous system; HbA1c, hemoglobin A1c.
result of COVID-19 infection and subsequent dehydration, electrolyte disturbances, nausea, and gastrointestinal upset, which are also common adverse effects of hydroxychloroquine and may further exacerbate severe cardiac dysrhythmias.\textsuperscript{42}

We have identified medications that may interact with studies drugs that could be deprescribed proactively or at the time of treatment (eg, off-label low-dose quetiapine for sleep and agitation). Others, if stopped abruptly, could lead to serious adverse drug withdrawal events or uncomfortable withdrawal symptoms (eg, methadone or higher doses of SSRIs).\textsuperscript{43} Finally, some medications have long half-lives that require weeks to months to discontinue safely and avoid interactions. In this case, it may not be possible to stop the medication in time for treatment, and thus the risk of interaction will not be reduced (eg, azithromycin,\textsuperscript{44} fluoxetine, and amiodarone). Of note, although there is a risk of potential interactions between medications, this does not necessarily mean there will be any clinical manifestations.

Currently, the use of antimalarials for the treatment or prevention of COVID-19 has extremely limited evidence.\textsuperscript{27} If robust evidence demonstrating efficacy in the treatment of COVID-19 is established, some clinicians might opt to continue certain medications that cannot be stopped abruptly or where symptoms of withdrawal are thought to be significant. In most cases, this would involve judicious monitoring of the QTc and minimizing other risk factors (electrolyte abnormalities, bradycardia). Although cardiac monitoring is generally available for hospitalized patients, and perhaps at select nursing homes, this is likely not the case for most outpatients. Finally, it is important to consider the half-life of the treatment medication to know for how long symptoms should be monitored and when it is safe to restart medications (hydroxychloroquine, range = 20-120 days; mean = 40 days).\textsuperscript{45-47}

The risk of QTc prolongation may persist beyond the treatment period and remain clinically relevant for an unclear duration.

Of note, the optimal effective dose of hydroxychloroquine is not known. Our referenced study uses a daily dose of 600 mg, but in practice doses are variable, and some jurisdictions may prescribe lower doses of 400 mg daily that may have an impact on the risk of drug interactions and of side effects. These considerations aside, for medications that are PIMs, their interactions with possible COVID-19 therapies are yet another reason to evaluate these medications for safe deprescribing immediately.\textsuperscript{48} Any concern for abrupt discontinuation can be avoided by deprescribing in advance of acute illness.\textsuperscript{48}

Although we used hydroxychloroquine as a test case, this should not be interpreted as an endorsement of the medication. The clinical scenario described here is not limited to hydroxychloroquine. Other treatments including but not limited to lopinavir-ritonavir, colchicine, and dapsone have also been proposed. These treatments similarly do not have significant evidence to support their use presently, but they also carry risks of serious drug-drug interactions.\textsuperscript{48,49}

Clinicians may be tempted and indeed are prescribing medications out of desperation to provide patients with some form of treatment for COVID-19, but caution and a rigorous review of possible interactions is warranted, especially in older adults with polypharmacy. Notably, this population will often be underrepresented in clinical trials and even if proven effective, harms may still outweigh benefits for some therapies. An individualized approach should always be taken. Presently, although some medications have shown promise, such as hydroxychloroquine and more recently remdesivir,\textsuperscript{49} no medication for the treatment of COVID-19 has been proven effective, and so we would suggest that outside of a clinical trial, the potential harms of off-label prescribing likely outweigh benefits. In the meantime, it is important that we reduce the number of PIMs patients are taking because it may facilitate more treatment options once clinical evidence is established.

Strengths of this study include a large cohort of older adults from a multisite trial with polypharmacy, a thorough review of the literature to outline potential drug interactions, and clear instructions for medication management in the setting of drug interactions. This cohort also reflects the latest FDA recommendation that hydroxychloroquine should not be used outside of a clinical trial or a hospitalized setting.\textsuperscript{14}

Our study also has several limitations. Because they were all hospitalized, the patients in this study likely represent those who are most likely to experience harm as a result of widespread prescribing of hydroxychloroquine. Future work should focus on finding safe and effective treatments in long-term care facilities where the burden of polypharmacy is high, there is an increased risk for COVID-19 exposure, and effective treatments may decrease the risk of hospitalization. We chose to focus on hydroxychloroquine as a test case to provide realistic examples of harm that could result from widespread prescribing. Reviewing all potential therapies and their subsequent drug-drug interactions was beyond the scope of this article. However, similar recommendations could be generated for other potential treatments and may be more complex. For example, interactions with lopinavir-ritonavir are more extensive than we have outlined for hydroxychloroquine.

Additionally, the clinical significance of the interactions identified vary with cardiac complications, with sudden death the most severe, whereas absolute risks of seizure or hypoglycemia are less well defined. All patients in our cohort were on at least five medications. This is the case for approximately 50% of older Americans.\textsuperscript{24,25} For those on fewer medications, the risk of drug-drug interactions is less. However, this study only looked at interactions with home medications. Patients who are hospitalized may have an even higher risk of interactions because they receive additional treatments (eg, concurrent antibiotics that prolong the QTc, antipsychotics for the management of delirium, insulin, etc). Finally, although the population of patients we analyzed is Canadian, the problem of polypharmacy has been widely described in the United States and countries across the world, so the principles outlined in the discussion can be extrapolated to other jurisdictions.

In conclusion, polypharmacy has many unpredictable consequences. There are well-described harms (eg, falls, fractures, and cognitive impairment),\textsuperscript{23} but we describe an emerging concern in the era of COVID-19. Patients may not be eligible for COVID-19 trials to study the effectiveness and safety of the medications under investigation. Others may be subject to harm as a result of off-label prescribing due to the risk of drug-drug interactions. Now more than ever, we should examine the medication lists of older adults with a focus on medication optimization and
stopping PIMs, particularly those that may interact with potential COVID-19 therapies.

ACKNOWLEDGMENTS

We wish to thank the patients who enrolled in the original MedSafer study who agreed to participate in research into polypharmacy.

Financial Disclosure: Funding for this project was provided by the Centre for Aging and Brain Health Innovation, the Canadian Frailty Network, and the Fonds de recherche du Québec - Santé.

Conflict of Interest: Todd Lee and Emily McDonald receive research funding from the Fonds de recherche du Québec – Santé, and they are co-owners of MedSafer Corp (an electronic software for deprescribing referenced in the study). The remaining authors have declared no conflicts of interest for this article.

Author Contributions: Study concept: McDonald, Ross, and Lee. Drafting of the manuscript: Ross and McDonald. Revision of the manuscript: All authors. Approval of the manuscript: All authors. Data analysis: Goodwin Wilson, McDonald, and Lee.

Sponsor’s Role: The agencies were not involved in the drafting or revision of the manuscript.

REFERENCES

1. World Health Organization. Pneumonia of unknown cause—China. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/. Accessed May 15, 2020.
2. World Health Organization. Novel coronavirus—China. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed May 15, 2020.
3.世界卫生组织. 新型冠状病毒—中国. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Accessed May 13, 2020.
4. WorldOmeter. COVID-19 coronavirus pandemic. https://www.worldometers.info/coronavirus. Accessed May 13, 2020.
5. National Institutes of Health U.S. National Library of Medicine. https://clinicaltrials.gov/. Accessed April 29, 2020.
6. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):260-271.
7. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.03.22.20047583v3.
8. LD CHEN J, Li LIU, Ping LIU, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49(2):215-219.
9. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4.23):e2008857.
10. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73.
11. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a combination for hydrogenchloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;30:101663.
12. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob. Agents. 2020;10:90.
13. Bright R. Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 coronavirus disease. Silver Spring, Maryland: US Department of Health and Human Services. U.S. Food and Drug Administration; 2020. https://www.ncbi.nlm.nih.gov.proxy3.library.mcgill.ca/pmc/articles/PMC715171/. Accessed May 31, 2020.
14. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. Close supervision is strongly recommended. Administration U.S. Food and Drug Administration; 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-chloroquine-covid-19-outside-hospital-setting. Accessed May 31, 2020.
15. Sanders JM, Monogue ML, Jodlowski TZ, Caturelli JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. In press.
16. Rowland C. FDA authorizes widespread use of unproven drugs to treat coronavirus, saying possible benefit outweighs risks. Washington Post. https://www.washingtonpost.com/business/2020/03/30/coronavirus-drugs-hydroxychloroquine-chloroquine/. Accessed April 15, 2020.
17. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020. In press.
18. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed May 12, 2020.
19. EK MC, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020;7(4):ofaa105.
20. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574-1581.
21. Applegate WB, Ouslander JG. COVID-19 presents high risk to older persons. J Am Geriatr Soc. 2020;68(4):681-681.
22. Masnou N, Shakib S, Kalisch-Ellott L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230-230.
23. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly, Expert Opin Drug Saf. 2014;13(1):57-65.
24. Ellenbogen MI, Wang P, Overton HN, et al. Frequency and predictors of polypharmacy in US Medicare patients: a cross-sectional analysis at the patient and physician levels. Drugs Aging. 2020;37(1):57-65.
25. Medication Overload: America’s Other Drug Problem; How the drive to prescribe is harming older Americans. Lown Institute; 2019. https://lowninstitute.org/reports/medication-overload-americas-other-drug-problem/. Accessed May 15, 2020.
26. Hamilton HJ, Gallagher PF, O’Mahony D. Inappropriate prescribing and adverse drug events in older people. BMC Geriatr. 2009;9:5-5.
27. Pastik KA, Okafor EC, Wang F, et al. Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis. 2020;7(4):130. doi: 10.1093/ofid/ofaa130.
28. Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients PIMs defined by STOPP criteria and risk of ADEs. Arch Intern Med. 2011;171(11):1013-1019.
29. Gallagher P, Lang PO, Cherubini A, et al. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals, Eur J Clin Pharmacol. 2011;67(11):1175.
30. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674-694.
31. Choosing Wisely Canada Recommendations. https://choosingwiselycanada.org/recommendations/. Accessed April 15, 2020.
32. McDonald EG, Wu PE, Rashidi B, et al. The MedSafer study: a controlled trial of an electronic decision support tool for deprescribing in acute care. J Am Geriatr Soc. 2019;67(9):1843-1850.
33. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPPSTART criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-218.
34. Product monograph including patient medication information plaquenil. Sanofi-Aventis Canada Inc.; 2019. http://products.sanofi.ca/en/plaquinil.pdf. Accessed May 31, 2020.
35. Hydroxychloroquine drug Interactions. https://www.drugs.com/drug-interactions/hydroxychloroquine-index.html. Accessed April 15, 2020.
36. Woosley R, Heise CW, Romero KA. QTDrug List. AZCERT. www.crediblemeds.org. Accessed April 27, 2020.
37. Fact sheet for health care providers emergency use authorization (EUA) of Hydroxychloroquine Sulfate supplied from the strategic National stockpile for treatment of COVID-19 in certain hospitalized patients. U.S. Food and Drug Administration; 2020. https://www.fda.gov/media/136337/download. Accessed May 31, 2020.
38. American Hospital Formulary Service. Pharmacologic-therapeutic classification system. https://www.oregon.gov/obnm/rules/AHSClassificationWithDrugs.pdf. Accessed April 15, 2020.
39. Rockwood K, Song X, Macknight G, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-495.
40. Roden Dan M, Harrington Robert A, Poppas A, Russo Andrea M. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation. doi: 10.1161/CIRCULATIONAHA.120.047521. Accessed April 8, 2020.

41. Malone MLH, Perry A, Biese K, Bonner A, Pagel P, Unroe KT. COVID-19 in older adults: key points for emergency department providers. J Geriatr Emerg Med. 2020;1(4). https://gedcollaborative.com/article/covid-19-in-older-adults-key-points-for-emergency-department-providers/. Accessed May 31, 2020.

42. Graves T, Hanlon JT, Schmader KE, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med. 1997;157(19):2205-2210.

43. Przybyla H. Family of New York woman blames hydroxychloroquine combo for fatal heart attack. https://www.nbcnews.com/health/health-news/family-new-york-woman-blames-hydroxychloroquine-combo-fatal-heart-attack-n1185451. Accessed April 27, 2020.

44. Plaquenil hydroxychloroquine sulfate tablets, USP. U.S. Food and Drug Administration; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf. Accessed date May 31, 2020.

45. Fan H-W, Ma Z-X, Chen J, Yang X-Y, Cheng J-L, Li Y-B. Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC-MS/MS. Rheumatol Ther. 2015;2(2):183-195.

46. Hydroxychloroquine: drug information lexicomp. https://www.uptodate.com/contents/hydroxychloroquine-drug-information. Accessed April 28, 2020.

47. University of Maryland School of Pharmacy. Optimizing medication management during the COVID-19 pandemic: Implementation guide for post-acute and long-term care; 2020. https://www.umaryland.edu/news/archived-news/april-2020/optimizing-medication-management-in-covid-19-pandemic.php. Accessed May 31, 2020.

48. Grein J, Ohmagari N, Shin D, et al. Compassionate use of Remdesivir for patients with severe Covid-19. N Engl J Med. 2020. doi: 10.1056/NEJMoa2007016.

49. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-1799. doi: 10.1056/NEJMoa2001282.